Bright Green Partners with Benuvia Operations
Bright Green Corporation (Nasdaq: BGXX) has announced an important partnership through a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leading name in pharmaceutical cannabinoids. This collaboration highlights Bright Green's dedication and capability to deliver high-quality organic materials to pharmaceutical entities in the U.S.
Homegrown Supply Agreement
This agreement underscores Bright Green’s capacity to fulfill the demand for quality raw materials within the pharmaceutical sector. As part of this supply deal, Benuvia intends to leverage Bright Green’s unique position to manufacture Schedule I & II raw materials while strictly following Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations, all within the United States. Such adherence guarantees the production of domestically sourced cGMP, pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) for both U.S. and global markets.
Strategic Growth for Bright Green
This partnership strengthens Bright Green's strategy to become the premier supplier of plant-based raw materials for the production of cannabinoid, psychedelic, and opioid-related drugs in the United States. The company is also currently engaged in a new fundraising round and is forming additional supply agreements, positioning itself for significant performance improvements in the upcoming year.
DEA Compliance and Future Operations
The recent completion of the Drug Enforcement Administration (DEA) annual operational procedures for the cultivation and manufacturing of Schedule I & II drugs marks a crucial milestone for Bright Green, positioning the company favorably to commence operations. Meeting these stringent national standards is vital for Bright Green’s mission to supply essential materials to the pharmaceutical sector, further fostering innovation within the industry.
About Bright Green Corporation
Bright Green is one of the few companies authorized by the U.S. government and the New Mexico Board of Pharmacy to cultivate, manufacture, and legally sell Schedule I and II plant-derived drugs for research, pharmaceutical applications, and related exports. The company’s approval from the U.S. Drug Enforcement Administration aligns with its vision to improve quality of life through the opportunities presented by cannabis and other plant-based therapies.
About Benuvia Operations, LLC
Benuvia Operations, LLC is a leader in the pharmaceutical industry, excelling in the research, development, and commercialization of innovative pharmaceutical products across various therapeutic areas. Their commitment to patient outcomes is evident in their rigorous scientific methodologies and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia stands as a trusted entity. Their flagship product, SYNDROS, is an FDA-approved medication designed to help manage weight loss related to anorexia in AIDS patients and to alleviate nausea and vomiting caused by chemotherapy.
Media Inquiries & Investor Relations Contact
For media inquiries or investor relations, please reach out to: ir@brightgreen.us
Frequently Asked Questions
What is the significance of the partnership between Bright Green and Benuvia?
This partnership enables Bright Green to supply high-quality raw materials necessary for Benuvia's pharmaceutical applications, especially in the cannabinoid and psychedelic sectors.
How does Bright Green ensure compliance with regulations?
Bright Green follows Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations in its operations to maintain compliance.
What is Bright Green's vision for the future?
Bright Green aims to establish itself as the leading domestic supplier of plant-based raw materials for the pharmaceutical industry, enhancing quality of life through innovative therapies.
What products does Benuvia specialize in?
Benuvia focuses on developing pharmaceutical products that cater to various therapeutic needs, including their flagship product SYNDROS, which assists patients dealing with anorexia and the side effects of chemotherapy.
How can interested parties learn more about Bright Green?
Individuals can visit www.brightgreen.us to find more information about Bright Green Corporation and its initiatives.
